Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giusy Cetani

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Expert Review of Anticancer Therapy|May 17, 2018
A look at treatment strategies for relapsed multiple myelomaGiusy Cetani, Mario Boccadoro, Stefania Oliva
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Current Medicinal Chemistry|May 15, 2018
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple MyelomaMattia D'Agostino, Giulia Gazzera, Giusy Cetani, et al.
Cytotherapy|March 11, 2024
Epigenetic challenges on the horizon of chimeric antigen receptor-TGiuditta Benincasa, Maria Grazia Strozziero, Maria Assunta Di Pastena, et al.
Annals of Hematology|July 15, 2020
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantationVincenzo Apolito, Luisa Giaccone, Simone Ferrero, et al.
Frontiers in Cardiovascular Medicine|May 10, 2021
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma PatientsGiulia Mingrone, Anna Astarita, Lorenzo Airale, et al.
Cancers|April 30, 2021
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events PredictionAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Targeted Oncology|September 25, 2023
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life ExperienceDanilo De Novellis, Raffaele Fontana, Salvatore Palmieri, et al.
Hematological Oncology|January 14, 2026
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient JourneyLisa Argnani, Cinzia Pellegrini, Ombretta Annibali, et al.
European Journal of Haematology|October 6, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsDanilo De Novellis, Daniele Derudas, Donatella Vincelli, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Expert Review of Anticancer Therapy|May 17, 2018
A look at treatment strategies for relapsed multiple myelomaGiusy Cetani, Mario Boccadoro, Stefania Oliva
Clinical Hematology International|October 1, 2021
Moving Toward Continuous Therapy in Multiple MyelomaFrancesca Bonello, Giusy Cetani, Luca Bertamini, et al.
Current Medicinal Chemistry|May 15, 2018
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple MyelomaMattia D'Agostino, Giulia Gazzera, Giusy Cetani, et al.
Cytotherapy|March 11, 2024
Epigenetic challenges on the horizon of chimeric antigen receptor-TGiuditta Benincasa, Maria Grazia Strozziero, Maria Assunta Di Pastena, et al.
Annals of Hematology|July 15, 2020
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantationVincenzo Apolito, Luisa Giaccone, Simone Ferrero, et al.
Frontiers in Cardiovascular Medicine|May 10, 2021
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma PatientsGiulia Mingrone, Anna Astarita, Lorenzo Airale, et al.
Cancers|April 30, 2021
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events PredictionAnna Astarita, Giulia Mingrone, Lorenzo Airale, et al.
Targeted Oncology|September 25, 2023
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life ExperienceDanilo De Novellis, Raffaele Fontana, Salvatore Palmieri, et al.
Hematological Oncology|January 14, 2026
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient JourneyLisa Argnani, Cinzia Pellegrini, Ombretta Annibali, et al.
European Journal of Haematology|October 6, 2024
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsDanilo De Novellis, Daniele Derudas, Donatella Vincelli, et al.
Pageof 1